Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 12.

Panigrahy, D; Edin, M L; Lee, C R; Huang, S; Bielenberg, D R; Butterfield, C E; Barnés, C M; Mammoto, A; Mammoto, T; Luria, A; Benny, O; Chaponis, D M; Dudley, A C; Greene, E R; Vergilio, J A; Pietramaggiori, G; Scherer-Pietramaggiori, S S; Short, S M; Seth, M; Lih, F B; Tomer, K B; Yang, J; Schwendener, R A; Hammock, B D; Falck, J R; Manthati, V L; Ingber, D E; Kaipainen, A; D'Amore, P A; Kieran, M W; Zeldin, D C (2012). Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. Journal of Clinical Investigation, 122(1):178-191.

Nasser, M W; Qamri, Z; Deol, Y S; Ravi, J; Powell, C A; Trikha, P; Schwendener, R A; Bai, X F; Shilo, K; Zou, X; Leone, G; Wolf, R; Yuspa, S H; Ganju, R K (2012). S100A7 Enhances Mammary Tumorigenesis through Upregulation of Inflammatory Pathways. Cancer Research, 72(3):604-615.

Vuarchey, C; Kumar, S; Schwendener, R A (2011). Albumin coated liposomes: a novel platform for macrophage specific drug delivery. Nanotechnology Development, 1(1):e2.

Zattoni, M; Mura, M L; Deprez, F; Schwendener, R A; Engelhardt, B; Frei, K; Fritschy, J M (2011). Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. Journal of Neuroscience, 31(11):4037-4050.

Bijnsdorp, I V; Schwendener, R A; Schott, H; Fichtner, I; Smid, K; Laan, A C; Schott, S; Losekoot, N; Honeywell, R J; Peters, G J (2011). Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine. Investigational New Drugs, 29(2):248-257.

Schott, H; Goltz, D; Schott, T C; Jauch, C; Schwendener, R A (2011). N(4)-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate). Bioorganic & Medicinal Chemistry, 19(11):3520-3526.

Egilmez, N K; Harden, J L; Virtuoso, L P; Schwendener, R A; Kilinc, M O (2011). Nitric oxide short-circuits interleukin-12-mediated tumor regression. Cancer Immunology, Immunotherapy, 60(6):839-845.

Yang, H; Kim, C; Kim, M J; Schwendener, R A; Alitalo, K; Heston, W; Kim, I; Kim, W J; Koh, G Y (2011). Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Molecular Cancer, 10:36.

Treiger Borema, S E; Schwendener, R A; Osso, J A; de Andrade, H F; Nascimento, N (2011). Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. International Journal of Antimicrobial Agents, 38(4):341-347.

Schwendener, R A; Schott, H (2010). Liposome formulations of hydrophobic drugs. In: Weissig, V. Liposomes, Methods and Protocols, Vol. 1: Pharmaceutical Nanocarriers. New York, NY, USA: Humana Press, 129-138.

Schwendener, R A; Ludewig, B; Cerny, A; Engler, O (2010). Liposome-based vaccines. In: Weissig, V. Liposomes, Methods and Protocols, Vol. 1: Pharmaceutical Nanocarriers. New York, NY, USA: Springer, 163-175.

Westwood, J A; Haynes, N M; Sharkey, J; McLaughlin, N; Pegram, H J; Schwendener, R A; Smyth, M J; Darcy, P K; Kershaw, M H (2009). Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice. Clinical Cancer Research, 15(24):7624-7633.

This list was generated on Thu Sep 21 15:32:17 2017 CEST.